{"id":37185,"date":"2026-03-25T09:28:00","date_gmt":"2026-03-25T13:28:00","guid":{"rendered":"https:\/\/www.drugpatentwatch.com\/blog\/?p=37185"},"modified":"2026-03-08T14:22:25","modified_gmt":"2026-03-08T18:22:25","slug":"win-the-deal-before-the-patent-drops-how-regulatory-and-legal-service-firms-can-build-a-repeatable-high-margin-revenue-stream-by-delivering-patent-landscape-intelligence-in-the-five-years-before-cli","status":"publish","type":"post","link":"https:\/\/www.drugpatentwatch.com\/blog\/win-the-deal-before-the-patent-drops-how-regulatory-and-legal-service-firms-can-build-a-repeatable-high-margin-revenue-stream-by-delivering-patent-landscape-intelligence-in-the-five-years-before-cli\/","title":{"rendered":"Win the Deal Before the Patent Drops: How regulatory and legal service firms can build a repeatable, high-margin revenue stream by delivering patent landscape intelligence in the five years before clients’ blockbusters go generic"},"content":{"rendered":"\n

The Five-Year Window Is Not Generous<\/h2>\n\n\n\n
\"\"<\/figure>\n\n\n\n

When a branded drug loses patent exclusivity, its manufacturer does not get to negotiate the terms of decline. Generic manufacturers file. Prices drop, sometimes 80 percent in the first year. Revenue that once funded five pipeline candidates evaporates. The pharmaceutical company’s legal team, which probably should have been monitoring secondary patents, formulation filings, and international exclusivity extensions eighteen months earlier, scrambles to find leverage it no longer has.<\/p>\n\n\n\n

This is your client’s problem before it becomes your opportunity. Regulatory and legal service firms that understand the pre-loss of exclusivity (LOE) window not as an abstract risk management concept but as a specific, time-sequenced intelligence challenge are positioned to offer one of the most defensible service products in biopharma professional services: the patent landscape update.<\/p>\n\n\n\n

The five-year horizon before LOE is not arbitrary. It is the window in which branded manufacturers can realistically act on information. Patent term extension applications under 35 U.S.C. \u00a7 156 must be filed within 60 days of approval, and most of the regulatory work to support them happens years earlier. Pediatric exclusivity strategies require clinical planning that cannot happen in twelve months. Authorized generic partnerships take time to structure. Formulation patents that could survive the originator’s composition-of-matter expiry must be prosecuted years before they are needed. Five years is about the minimum runway for meaningful action; anything shorter is mostly litigation preparation.<\/p>\n\n\n\n

For your firm, that means client outreach needs to happen when branded manufacturers still have room to maneuver. A patent landscape report delivered six months before LOE is a post-mortem. The same analysis delivered five years out is a strategic asset.<\/p>\n\n\n\n

What LOE Actually Triggers<\/h3>\n\n\n\n

Loss of exclusivity is not a single event. It is a sequence of triggers that each carry different commercial consequences. The first ANDA filer with a Paragraph IV certification can enter the market 180 days before all other generics if they successfully challenge patents listed in the FDA’s Orange Book. Authorized generic agreements can neutralize part of that first-filer advantage but require coordination that has to be structured well in advance. Multiple biosimilar entrants, operating under the 12-year biologics exclusivity framework established by the Biologics Price Competition and Innovation Act (BPCIA), create a different entry pattern entirely.<\/p>\n\n\n\n

Each of these triggers has patent implications. Every patent listed in the Orange Book for a branded product is a potential target for a Paragraph IV challenge. Every unlisted secondary patent is a potential asset that has not been deployed. The firms that map this terrain comprehensively — before their client’s competitors do — deliver something with quantifiable value.<\/p>\n\n\n\n

$251BEstimated branded drug revenue at risk from LOE events between 2024 and 2030, according to IQVIA’s annual medicine spend outlook.[1]<\/sup><\/p>\n\n\n\n

The Revenue Destruction Timeline<\/h3>\n\n\n\n

Academic literature and IQVIA data are consistent on the shape of generic erosion. In markets with four or more generic entrants, branded drugs typically lose 75 to 90 percent of their unit volume within twelve months of generic launch.[2]<\/sup> In small-molecule oral solid dose markets, price erosion can reach 95 percent within two years. The original branded product frequently survives only as a specialty or patient-assistance vehicle, not a commercial revenue driver.<\/p>\n\n\n\n

Biologics face a different but accelerating curve. Biosimilar penetration rates in the U.S. remain lower than in Europe because of physician switching inertia and payer contracting complexity, but the gap is narrowing as biosimilar manufacturers invest more in commercial infrastructure. Humira’s experience post-LOE in 2023, with over two dozen biosimilars eventually entering a market that had generated $21 billion in annual U.S. revenue for AbbVie, is the case study that every large-molecule brand team currently studies.[3]<\/sup><\/p>\n\n\n\n

For clients managing products in this revenue range, the value of intelligence that changes a single strategic decision — extend a patent term, identify a challengeable generic filing, or structure an authorized generic deal — is orders of magnitude larger than any professional service fee. That asymmetry is the business case for your firm’s pre-LOE service offering.<\/p>\n\n\n\n

Why Regulatory and Legal Firms Own This Market<\/h2>\n\n\n\n

Consulting firms can produce patent landscape reports. In-house patent counsel can run their own surveillance programs. Investment banks model LOE impacts into equity research. So why should regulatory and legal service firms believe they have a structural advantage here?<\/p>\n\n\n\n

Two reasons. First, the regulatory dimension of pre-LOE strategy is inseparable from the patent analysis. Patent term restoration, pediatric exclusivity, orphan drug extensions, and the timing of sNDA filings are all regulatory actions with patent consequences. Understanding how a 505(b)(2) application affects Orange Book listing eligibility, or how a label change triggers a new period of exclusivity, requires regulatory expertise that a pure patent analytics firm does not have. Your firm’s depth in FDA regulatory strategy makes the landscape analysis substantively different from what a data vendor can produce.<\/p>\n\n\n\n

Second, legal service firms already have the client relationships that make this kind of early-stage advisory possible. Patent landscape updates are not transactional work. They are the beginning of a multi-year engagement. A firm that delivers a rigorous five-year-out analysis of a product’s exclusivity position has a legitimate reason to be in the room for every subsequent strategic discussion: lifecycle management, authorized generic structuring, patent litigation preparation, and regulatory filing decisions. The landscape report is not the end product. It is the entry point.<\/p>\n\n\n\n

\n

“The average brand team is managing seven to twelve patents per product, across multiple jurisdictions, with different expiry dates and challenge profiles. Most of them cannot tell you off the top of their heads which patents are actually Orange Book-listed versus which are merely assigned to the product.”– Quoted in a 2024 survey of pharmaceutical IP directors conducted by the Licensing Executives Society[4]<\/sup><\/p>\n<\/blockquote>\n\n\n\n

The Gap Between In-House Teams and Real Intelligence<\/h3>\n\n\n\n

In-house patent counsel at large pharma companies are talented and well-resourced, but they carry constraints that create demand for external service providers. They manage dockets that span dozens of products simultaneously. They are frequently organized by therapeutic area rather than by product lifecycle stage, which means no single team owns the pre-LOE monitoring function comprehensively. They also tend to be oriented toward prosecution and litigation rather than competitive intelligence, because those are the activities that generate measurable deliverables for internal stakeholders.<\/p>\n\n\n\n

Mid-size and specialty pharma companies have even larger gaps. A company with three to five marketed products may have a single patent attorney handling all prosecution, litigation risk, and regulatory coordination. That person does not have time to build and maintain a comprehensive landscape monitor for each product on a quarterly basis.<\/p>\n\n\n\n

Your firm fills that gap. The question is how to make the service specific enough to be genuinely useful rather than generic enough to be easily ignored.<\/p>\n\n\n\n

What a Patent Landscape Update Actually Contains<\/h2>\n\n\n\n

The phrase “patent landscape” is used loosely in the industry. For pre-LOE purposes, it needs a precise definition that you can defend to a skeptical Head of IP or Chief Legal Officer. A patent landscape update, as this guide uses the term, is a structured intelligence document that maps all patent protection relevant to a specific product’s commercial exclusivity, identifies threats to that exclusivity from generic or biosimilar competitors, and quantifies the time and probability dimensions of each threat and opportunity.<\/p>\n\n\n\n

That definition excludes two things that often inflate landscape reports without adding value: exhaustive prior art analyses and broad freedom-to-operate opinions. The pre-LOE client does not need to know everything that has ever been filed in a therapeutic class. They need to know what is protecting their revenue, what is threatening it, and what they can do about it in the time available.<\/p>\n\n\n\n

Orange Book and Purple Book Analysis<\/h3>\n\n\n\n

The FDA’s Orange Book (for small molecules) and Purple Book (for biologics) are the starting points for any pre-LOE patent map, but they are not comprehensive. The Orange Book lists only patents that the NDA holder has submitted for listing, and listing standards have been contested and litigated for decades. A patent that could be used defensively in litigation may not be listed in the Orange Book — either because the holder chose not to list it, because it did not meet FDA’s listing criteria, or because it was prosecuted after the product launched and was never linked to the NDA.<\/p>\n\n\n\n

The analytical task for your firm is to reconcile Orange Book listings against the full patent portfolio held by the brand manufacturer, identify gaps, and assess whether unlisted patents could be brought to bear against a generic filer. Platforms like DrugPatentWatch aggregate this data across products and update it continuously, allowing analysts to identify discrepancies between listed patents and the broader portfolio with efficiency that manual searches cannot match. For a product with 12 Orange Book patents and another 20 related filings in the portfolio, the landscape work of reconciling these sets, checking assignment chains, and tracking continuation and divisional applications is the core of the service.<\/p>\n\n\n\n

International Filing Clusters<\/h4>\n\n\n\n

U.S. exclusivity does not end a product’s global commercial story. Many branded manufacturers generate 40 to 60 percent of their revenue from ex-U.S. markets, and patent expiry dates differ by jurisdiction because of different patent term extension regimes, different prosecution histories, and different data exclusivity rules. A product with LOE in the U.S. in 2027 may retain exclusivity in Germany until 2029 and in Japan until 2030. Generic entrants in each market operate on separate timelines.<\/p>\n\n\n\n

The pre-LOE landscape update should capture, at minimum, the patent status in the EU (via the European Patent Office and national validations), Japan, Canada, and the top three to five emerging markets by revenue. This international dimension is frequently underdeveloped in in-house monitoring programs and represents one of the clearest areas where an external firm’s resources add value.<\/p>\n\n\n\n

Secondary Patent Web Mapping<\/h4>\n\n\n\n

The composition-of-matter patent — the core patent covering the active pharmaceutical ingredient — is usually the most prominent feature of a product’s exclusivity profile, and it is often the one that expires first. What sustains exclusivity after that date is a web of secondary patents covering formulations, dosing regimens, manufacturing processes, metabolites, polymorphs, salts, and specific patient populations. These secondary patents vary dramatically in their validity and enforceability. Some are robust; many are legally fragile.<\/p>\n\n\n\n

Mapping the secondary patent web serves two strategic purposes. For the brand manufacturer, it identifies which secondary patents are worth investing in defending and which are vulnerable to challenge. For litigation preparation, it identifies which patents a generic filer is likely to challenge in a Paragraph IV certification and how defensible each is. Both purposes are downstream of the same analytical product: a complete map of what exists and an honest assessment of its strength.<\/p>\n\n\n\n

“Most in-house teams are oriented toward prosecution and litigation. No single attorney owns pre-LOE monitoring comprehensively. That gap is your firm’s market.”<\/p>\n\n\n\n

How to Structure the Deliverable for Maximum Client Value<\/h3>\n\n\n\n

The format of the landscape update matters as much as its content. A 200-page patent list is not a landscape update. It is a data dump that a client’s team will read for three hours, extract four actionable items from, and then file permanently in a shared drive.<\/p>\n\n\n\n

The deliverable should be structured in four components. The first is an executive summary of no more than three pages that states the product’s exclusivity runway, identifies the two to four most significant threats to that runway, and provides a high-level strategic recommendation for each. The second component is the patent-by-patent analysis covering Orange Book listings, secondary patents, and international filings, organized by expiry date and risk tier. The third is a competitive intelligence section covering known generic and biosimilar development programs, including ANDA filings that have become public through FDA’s Paragraph IV certification disclosure process. The fourth is a monitoring protocol: specific events to watch, filing deadlines to track, and a recommended update cadence.<\/p>\n\n\n\n

This last section is critical for business development purposes. A landscape update that includes a built-in monitoring protocol creates a natural follow-on engagement. The client who receives a rigorous initial analysis and then a recommendation for quarterly updates has a reason to stay engaged with your firm for the full pre-LOE period.<\/p>\n\n\n\n

Building the Business Development Case<\/h2>\n\n\n\n

The service product is only as valuable as your ability to sell it to the right clients at the right time. Business development for pre-LOE patent landscape services requires a different approach than most legal and regulatory service selling, because you are selling anticipatory intelligence rather than reactive problem-solving. Most clients are not calling you with this need. You have to show them the need before they feel it.<\/p>\n\n\n\n

Drug Shortlisting Criteria<\/h3>\n\n\n\n

Not every branded drug approaching LOE is a viable target for your business development outreach. The ideal target has a large enough revenue base to make the investment in landscape intelligence commercially rational, a patent portfolio complex enough that the analysis adds genuine insight beyond what a basic Orange Book search would yield, and a manufacturer large enough to afford external advisory services but not so large that it has already built comprehensive in-house capabilities.<\/p>\n\n\n\n

Practically, this means looking at products with U.S. annual revenues between $500 million and $5 billion, with LOE dates in the five- to seven-year forward window, and with at least five Orange Book patent listings. Products with this profile generate enough revenue for the client to justify a six-figure advisory engagement and have complex enough patent situations that the landscape work produces genuine insight. DrugPatentWatch’s product database allows analysts to screen for exactly these parameters: revenue estimates, patent counts, expiry dates, and competitive filing activity can all be filtered to build a target list efficiently.<\/p>\n\n\n\n

Building the Prospect List<\/h3>\n\n\n\n

Once you have a shortlist of target products, the business development work requires mapping those products to specific decision-makers. The patent landscape service is not typically sold to procurement or legal operations. It is sold to the Head of IP or Chief Patent Counsel, often in coordination with the Vice President of Regulatory Affairs and the General Counsel. Each of these individuals has a different primary concern: the IP leader cares about portfolio strength and litigation readiness, the regulatory leader cares about how the landscape analysis informs filing strategy, and the General Counsel cares about risk management and liability exposure.<\/p>\n\n\n\n

Your outreach material should speak to all three concerns without trying to address all three simultaneously in a single document. A two-page business development brief that leads with the revenue-at-risk number for the specific product, moves quickly to the key patent vulnerabilities your preliminary analysis has identified, and closes with a clear scope of work for the initial engagement is more effective than a capabilities deck that describes your firm’s breadth of experience.<\/p>\n\n\n\n

The preliminary analysis is not busywork. Doing an honest 30-minute screening of a target product’s Orange Book listings and publicly available ANDA filing history before reaching out gives you specific, credible observations to make in the outreach. “We noticed that your composition-of-matter patent on Product X expires in Q3 2028, and there are currently three ANDA filers in the Paragraph IV queue that we have not seen you publicly comment on” is a far stronger opening than a generic pitch about your firm’s patent capabilities.<\/p>\n\n\n\n

Timing the Outreach<\/h3>\n\n\n\n

The optimal outreach window for the initial engagement is when the product’s LOE is five to six years away. Earlier than that, the client’s internal team may not yet have the urgency to engage external resources. Later than five years, and the options your analysis might reveal are increasingly foreclosed. The strategic value of the work diminishes as the runway shortens.<\/p>\n\n\n\n

There are also trigger events that create natural outreach opportunities outside this general window. A Paragraph IV certification filing is public once the patent holder receives notice, and it signals that a generic filer has identified vulnerable patents — which means the brand manufacturer now has an urgent need for exactly the analysis your firm can provide. A new formulation approval or label expansion can change the Orange Book listing profile and create a fresh strategic question. Changes in the regulatory exclusivity status — a pediatric exclusivity grant, an orphan drug designation, or a Fast Track designation for a follow-on product — can alter the exclusivity timeline in ways that the client’s team may not have fully mapped to the patent position.<\/p>\n\n\n\n

The Patent Categories That Actually Determine Exclusivity Duration<\/h2>\n\n\n\n

A pre-LOE landscape analysis is only useful if the analyst understands how different categories of patents translate into actual market exclusivity. The relationship between patent protection and commercial exclusivity is not one-to-one, and the client who understands this distinction makes better strategic decisions than the client who conflates the two.<\/p>\n\n\n\n

Composition of Matter vs. Formulation Patents<\/h3>\n\n\n\n

Composition-of-matter (CoM) patents, which cover the active pharmaceutical ingredient itself, are the strongest form of pharmaceutical patent protection. They cover any use of the molecule, regardless of dosage form, formulation, or indication. When a CoM patent is in force and survives challenge, it provides complete market exclusivity. When it expires or is invalidated, the API becomes fair game for any generic manufacturer.<\/p>\n\n\n\n

Formulation patents cover specific dosage forms, delivery technologies, combinations, or preparation methods. They are narrower in scope. A generic manufacturer can design around a formulation patent by developing a different formulation that achieves the same clinical result. The key question your landscape analysis needs to answer is: how difficult is that design-around in practice, and what clinical evidence would the generic manufacturer need to support a bioequivalence showing for an alternative formulation?<\/p>\n\n\n\n

For products like extended-release formulations, transdermal patches, or inhalation devices, formulation patents can be surprisingly durable. The generic manufacturer’s challenge is not just legal; it is also technical. Your analysis should assess the realistic difficulty of the design-around alongside the legal validity of the patent, because clients who understand the technical barrier often calibrate their enforcement strategy differently than clients who see only the legal landscape.<\/p>\n\n\n\n

Method of Use and Process Claims<\/h3>\n\n\n\n

Method-of-use patents cover specific therapeutic applications of an approved drug. They are a frequent target of “skinny label” strategies, where a generic manufacturer seeks approval for only the non-patented indications and carves out the patented indication from its label. The Caraco decision and subsequent litigation have defined the limits of this strategy, but it remains a viable path for generic manufacturers when method-of-use patents cover a subset of the branded product’s approved uses.[5]<\/sup><\/p>\n\n\n\n

Process patents cover manufacturing methods and are rarely listed in the Orange Book, because the FDA does not consider them relevant to the drug-drug substitution analysis. But they can still be enforced against generic manufacturers who use substantially similar manufacturing methods. The landscape analysis should identify process patents and flag them as potential litigation assets even when they are not Orange Book-listed.<\/p>\n\n\n\n

Evergreening Tactics You Must Map<\/h3>\n\n\n\n

Evergreening describes the strategy of extending a branded product’s effective commercial exclusivity beyond the primary patent term by developing and patenting incremental improvements: new formulations, new dosing schedules, new combinations, new indications. The practice is contested in policy circles but is legal and widely used.<\/p>\n\n\n\n

For the pre-LOE landscape analysis, evergreening matters in two directions. Your client may be actively pursuing evergreening strategies that you can help structure and optimize. Alternatively, if you represent a client on the generic side, evergreening by the brand manufacturer creates the obstacles your client needs to navigate. Either way, the landscape analysis must map existing evergreening patents and model which pending applications, if granted, would meaningfully extend market exclusivity.<\/p>\n\n\n\n

Case Study A<\/p>\n\n\n\n

How a Formulation Patent Cluster Extended Revenue by Four Years<\/h3>\n\n\n\n

A mid-size specialty pharmaceutical company with a branded cardiovascular drug faced a composition-of-matter patent expiry in 2021. Its in-house team had focused monitoring resources on Orange Book-listed patents. An external landscape review conducted in 2017 identified five additional formulation patents covering the extended-release mechanism that were not Orange Book-listed but were enforceable against generic manufacturers using similar release technology. The client elected to list three of these patents following a label amendment and pursued NDA supplements that supported the listings. The first-filer ANDA was amended following notice, adding 18 months to the litigation timeline. Two generic manufacturers abandoned their formulations and reformulated entirely, delaying market entry by approximately four years. The revenue protected over that period represented a multiple of several hundred times the cost of the initial landscape analysis and subsequent patent work.<\/p>\n\n\n\n

Using DrugPatentWatch as Your Primary Intelligence Layer<\/h2>\n\n\n\n

Building a pre-LOE patent landscape service without a purpose-built pharmaceutical patent database is theoretically possible and practically inefficient. The USPTO full-text database, the FDA’s Orange Book download files, ANDA approval databases, and international patent registries each provide pieces of the picture. A skilled analyst can assemble these sources manually. Most will find, after several months, that the assembly cost consumes the margin of the service.<\/p>\n\n\n\n

DrugPatentWatch is the most comprehensive commercial platform for pharmaceutical patent intelligence currently available. It aggregates Orange Book patent listings, patent expiry data, ANDA filing histories, Paragraph IV certifications, and patent litigation records into a single searchable interface, updated regularly to reflect FDA actions and court decisions. For the pre-LOE landscape service, it functions as the analytical foundation on which your firm’s regulatory and legal expertise is applied.<\/p>\n\n\n\n

What the Platform Gives You<\/h3>\n\n\n\n

The practical capabilities most relevant to pre-LOE analysis are four. First, product-level patent expiry summaries that show all Orange Book-listed patents for a given NDA, their expiry dates, and any available information on patent term extensions or exclusivity periods. Second, ANDA filing tracking that identifies which generic manufacturers have filed applications for a product, whether those filings include Paragraph IV certifications, and what patent challenges have been publicly disclosed. Third, historical litigation data showing which patents have been challenged and defended in Hatch-Waxman litigation and what the outcomes were. Fourth, exclusivity period tracking that distinguishes between patent-based protection and regulatory exclusivity periods (NCE, pediatric, orphan), which expire independently and on different schedules.<\/p>\n\n\n\n

DrugPatentWatch’s data is not a substitute for legal analysis. What it does is eliminate the most time-consuming part of the analytical workflow — the data collection — so that your attorneys and regulatory specialists can focus on interpretation, strategy, and client communication.<\/p>\n\n\n\n

How to Build a Monitoring Workflow Around It<\/h3>\n\n\n\n

For a portfolio of 10 to 15 client products under active pre-LOE monitoring, a practical workflow uses DrugPatentWatch alerts to flag material changes — new ANDA filings, Paragraph IV certification notices, patent expirations, exclusivity period changes — and routes those alerts to the responsible analyst for assessment within 48 hours. Monthly summaries for each product, consolidated into a client-facing dashboard, form the recurring deliverable. Quarterly deep-dive updates, triggered by material changes or delivered on schedule regardless of changes, represent the high-value advisory touchpoints where your firm’s strategic counsel is most visible.<\/p>\n\n\n\n

The monitoring workflow also generates the raw material for the business development activities described earlier. An analyst who watches a portfolio of 50 to 100 products, including products for which you do not yet have client engagements, is constantly generating observations that can be turned into credible, specific outreach to prospective clients.<\/p>\n\n\n\n

Hatch-Waxman Mechanics Every BD Professional Needs to Know<\/h2>\n\n\n\n

The Drug Price Competition and Patent Term Restoration Act of 1984, universally known as Hatch-Waxman, is the statutory framework that governs the relationship between branded and generic pharmaceutical manufacturers in the U.S. It established the ANDA pathway, the Paragraph IV certification mechanism, and the patent term restoration program. Thirty years of litigation have produced an elaborate body of case law on top of the statute. For a regulatory and legal firm building a pre-LOE service, the key operational elements are patent term restoration, pediatric exclusivity, and Paragraph IV litigation mechanics.<\/p>\n\n\n\n

Patent Term Extensions and Restoration<\/h3>\n\n\n\n

Patent term restoration under 35 U.S.C. \u00a7 156 partially compensates innovators for the patent term consumed by FDA regulatory review. The extension is calculated as one-half the IND phase period plus the full NDA review period, capped at five years and subject to an overall limit of 14 years of post-approval patent protection. Only one patent per NDA can receive a patent term extension, and the application must be filed within 60 days of the product’s first FDA approval.<\/p>\n\n\n\n

For pre-LOE analysis, two questions matter. First, did the brand manufacturer receive the maximum available extension for the most strategically valuable patent? Extensions are sometimes applied to patents that are not the most commercially significant, either because of filing timing or because the manufacturer’s strategy evolved after the extension election. Second, are there any terminal disclaimers or patent term adjustment issues that could affect the actual expiry date? Patent term adjustment under 35 U.S.C. \u00a7 154(b) adds days for USPTO processing delays and is a source of frequent calculation errors in commercial databases.<\/p>\n\n\n\n

Pediatric Exclusivity and Orphan Drug Add-Ons<\/h3>\n\n\n\n

Pediatric exclusivity, granted under the Best Pharmaceuticals for Children Act, adds six months to all existing patents and exclusivity periods for a drug when the manufacturer completes FDA-requested pediatric studies. This six-month addition is not a new patent or a new exclusivity period — it attaches to whatever patent or exclusivity protection is already in place. For a product with a patent expiring in December 2027, pediatric exclusivity pushes effective market exclusivity to June 2028.<\/p>\n\n\n\n

Orphan Drug designation grants seven years of market exclusivity for products treating diseases affecting fewer than 200,000 people in the U.S. This exclusivity is regulatory in nature, separate from any patent protection, and can coexist with or outlast the patent estate. Products with orphan status can maintain exclusivity even after all patents expire, provided the orphan exclusivity period has not itself expired.<\/p>\n\n\n\n

Both of these exclusivity types are tracked in DrugPatentWatch alongside patent data, which is important because the pre-LOE analysis that ignores regulatory exclusivity will systematically underestimate the true exclusivity runway for drugs in rare disease and pediatric indications. Conversely, a manufacturer who has not pursued available pediatric studies may be leaving six months of exclusivity on the table — a finding that your landscape analysis can surface as an actionable recommendation.<\/p>\n\n\n\n

Typical Pre-LOE Strategic Window<\/p>\n\n\n\n

T-7CoM patent prime; biosimilar IND filing<\/p>\n\n\n\n

T-6Begin landscape mapping; assess PTR & pediatric<\/p>\n\n\n\n

T-5First full landscape update; secondary patent review<\/p>\n\n\n\n

T-4ANDA watch active; Para IV prep; authorized generic talks<\/p>\n\n\n\n

T-3Quarterly monitoring; litigation scenario planning<\/p>\n\n\n\n

T-2Litigation active or settlement negotiation begins<\/p>\n\n\n\n

T-1AG launch prep; payer contracting strategy<\/p>\n\n\n\n

Paragraph IV Challenges as Competitive Signals<\/h3>\n\n\n\n

When a generic manufacturer files an ANDA with a Paragraph IV certification — asserting that the brand manufacturer’s listed patents are either invalid or will not be infringed by the generic product — it must notify the patent holder within 20 days of FDA accepting the filing. The patent holder then has 45 days to file a patent infringement suit. If it does, the FDA imposes a 30-month stay on ANDA approval, giving the parties time to litigate the patent challenge before the generic enters the market.<\/p>\n\n\n\n

For pre-LOE monitoring, Paragraph IV filings are one of the most important early warning signals. They tell you which products are actively targeted by generic manufacturers, which patents those manufacturers believe are weak enough to challenge, and how many potential entrants exist for each product. DrugPatentWatch tracks Paragraph IV certification history comprehensively, including multi-filer situations where the 180-day exclusivity race between first filers creates additional competitive dynamics.<\/p>\n\n\n\n

The Biologics Track: Biosimilar Entry and 12-Year Exclusivity<\/h2>\n\n\n\n

The BPCIA created a separate approval pathway for biosimilars and a separate exclusivity structure for reference biologics. Reference products receive 12 years of regulatory data exclusivity from the date of first licensure — separate from any patent protection — plus an additional four years of data exclusivity during which the FDA will not even accept a biosimilar application. Patent protection for biologics can extend well beyond this exclusivity period, and the patent landscape for large molecules is structurally different from small molecules in ways that affect the pre-LOE analysis.<\/p>\n\n\n\n

How Biologic Patent Clusters Differ<\/h3>\n\n\n\n

A small-molecule drug’s patent estate is typically organized around a limited number of core patents: one or two composition-of-matter patents, a handful of formulation patents, and a few method-of-use patents. The total is usually manageable. A biologic’s patent estate, particularly for a monoclonal antibody, can include hundreds of patents covering manufacturing processes, cell lines, purification methods, formulations, dosing regimens, device combinations, and specific patient populations. AbbVie’s Humira portfolio, which reportedly included over 130 patents that delayed biosimilar entry in the U.S. for years after the core composition patent expired, is the extreme case, but it illustrates the structural reality of large-molecule patent strategy.[6]<\/sup><\/p>\n\n\n\n

For the pre-LOE landscape analysis of a biologic, the manufacturing and process patents deserve the same attention as the clinical patents. A biosimilar developer who can demonstrate bioequivalence to the reference product still faces the question of whether its manufacturing process infringes any of the brand manufacturer’s process patents. The BPCIA’s patent dance — the formal exchange of patent lists and infringement contentions between the biosimilar applicant and the reference product sponsor — creates a structured litigation pathway, but it also generates public information about which patents each side considers material. That public information feeds back into your monitoring program.<\/p>\n\n\n\n

Reading the 351(l) Patent Dance<\/h3>\n\n\n\n

Section 351(l) of the Public Health Service Act governs the information exchange between biosimilar applicants and reference product sponsors. The biosimilar applicant provides its application and manufacturing information to the sponsor; the sponsor identifies patents it believes could be infringed; the parties negotiate and litigate. The outcomes of 351(l) exchanges, including the patents that end up in litigation and the ones that are dropped, provide a real-world assessment of which patents in a biologic’s portfolio are considered defensible by both parties.<\/p>\n\n\n\n

For a regulatory and legal firm advising a reference product sponsor five years before LOE, tracking early 351(l) activity — who has filed BLA-compliant applications, which patents are being challenged, and what the litigation timeline looks like — is a core monitoring function. The same data, read from the biosimilar side, tells a biosimilar developer which patents need to be designed around and which are most likely to fall in litigation.<\/p>\n\n\n\n

Structuring and Pricing the Service<\/h2>\n\n\n\n

The patent landscape update as a service product can be structured in several ways, and the right structure depends on your firm’s existing relationships, billing model, and client mix. Two principal models work well for pre-LOE intelligence services: the project-based initial engagement and the subscription-based monitoring retainer.<\/p>\n\n\n\n

Tiered Engagement Models<\/h3>\n\n\n\n

The project-based model delivers a comprehensive initial landscape update for a specific product, priced on a fixed-fee basis. For a mid-complexity small-molecule product with 8 to 12 Orange Book patents and active ANDA competition, a credible initial landscape takes 60 to 80 attorney\/analyst hours to produce. Billing rates vary by firm, but the $25,000 to $60,000 range for initial landscape reports is consistent with what the market supports for well-regarded regulatory and legal service providers. Larger biologics products with complex patent estates and multiple jurisdictions can justify initial engagements in the $80,000 to $150,000 range.<\/p>\n\n\n\n

The subscription model provides ongoing monitoring and quarterly update reports for a monthly or annual retainer. This model has better margin characteristics for your firm because the incremental cost of producing each quarterly update is lower than the initial analysis, and the retainer revenue is predictable. Clients who have received the initial analysis and understand what they are getting typically renew monitoring retainers readily when the intelligence has proven useful.<\/p>\n\n\n\n

Recurring Intelligence vs. One-Time Reports<\/h3>\n\n\n\n

The recurring model is clearly preferable from a business development perspective, but it requires that you deliver genuine value in each quarterly update rather than a rehashed summary of unchanged data. The discipline of the monitoring workflow — identifying material changes, assessing their strategic implications, and surfacing them to the client promptly — is what makes quarterly updates worth a retainer. A quarterly report that says “no material changes since last quarter” without explaining what was reviewed and what the absence of change means is a cancellation risk.<\/p>\n\n\n\n

The most effective pre-LOE monitoring retainers include a defined trigger protocol: specific types of events (new ANDA filings, Paragraph IV certifications, patent expirations, court decisions affecting the patent estate) that generate an immediate client notification outside the regular reporting cycle. The client understands that they are not waiting for the quarterly report to learn about material developments. That responsiveness is what justifies the retainer fee.<\/p>\n\n\n\n

What Clients Actually Pay For<\/h3>\n\n\n\n

Clients who renew pre-LOE monitoring engagements year after year consistently cite two things: specific instances where early warning changed a strategic decision, and the confidence that comes from knowing someone is watching. The second benefit is harder to quantify but represents real value to a brand team that has a $2 billion product approaching LOE and limited internal bandwidth to monitor it comprehensively.<\/p>\n\n\n\n

The ROI framing for your business development conversations should be specific. If your landscape analysis identifies a secondary patent that the client had not considered listing in the Orange Book and that patent, when listed, triggers a 30-month stay following a Paragraph IV challenge, the value of that identification is the revenue generated during the stay period. For a product generating $1 billion annually, 30 months of protection is worth roughly $2.5 billion. The cost of your analysis and monitoring program is, in that context, a rounding error.<\/p>\n\n\n\n

Case Study B<\/p>\n\n\n\n

A Paragraph IV Filing Exposes an Unmonitored Secondary Patent<\/h3>\n\n\n\n

A specialty pharmaceutical company received a Paragraph IV certification notice on a branded CNS product with roughly $800 million in annual revenues. Its in-house team reviewed the listed patents challenged in the certification and concluded the litigation position was strong. An external landscape review, commissioned after the certification notice arrived, identified a method-of-use patent that was not Orange Book-listed but covered the product’s primary approved indication. The patent had been prosecuted from a continuation application filed four years after product launch and had not been connected to the NDA in the brand team’s internal records. The company elected to list the patent following an NDA supplement, which required the generic filer to amend its Paragraph IV certification to address the newly listed patent. The additional litigation extended the stay period, and the settlement that ultimately concluded the litigation included a delayed generic entry date that had not been available before the landscape review. The cost of the external review was recovered within the first week of the extended exclusivity period.<\/p>\n\n\n\n

Operationalizing the Service: Internal Team and Workflow<\/h2>\n\n\n\n

A pre-LOE patent landscape service is a multidisciplinary product. It requires patent law expertise to assess validity and enforceability, regulatory expertise to interpret exclusivity periods and Orange Book listing eligibility, competitive intelligence skills to monitor ANDA filings and generic manufacturer strategies, and project management capability to keep monitoring workflows current across a portfolio of client products. Few law firms have all four capabilities integrated into a single practice group, which is why the service is underprovided relative to client demand.<\/p>\n\n\n\n

Who Builds the Landscape<\/h3>\n\n\n\n

The most effective team structure for this service combines a patent attorney at the lead, a regulatory specialist as a co-author for the exclusivity and FDA dimensions, and a trained patent analyst or paralegal for the data assembly and monitoring functions. The attorney and regulatory specialist do not need to spend 60 hours on every landscape. Their involvement is concentrated at the interpretive and advisory stages. The analyst handles the systematic work: running DrugPatentWatch searches, pulling USPTO assignment records, tracking ANDA databases, and assembling the data foundation that the attorneys interpret.<\/p>\n\n\n\n

This structure keeps billing rates appropriate to the task and allows the service to scale without requiring partner-level time on every monitoring update. A single attorney can oversee monitoring programs for 10 to 15 client products if the analyst infrastructure is well-organized.<\/p>\n\n\n\n

The Client Reporting Cadence<\/h3>\n\n\n\n

Quarterly reporting works for most pre-LOE monitoring situations when the product’s LOE is more than three years away. Inside the three-year window, or when there is active Paragraph IV litigation, monthly reporting better reflects the pace of material developments. Annual comprehensive reviews, benchmarking the current patent position against the initial landscape analysis, provide the structured checkpoint that helps clients see how their situation has evolved and what strategic actions have been taken or missed.<\/p>\n\n\n\n

Client communication outside the regular reporting cycle should be immediate for Paragraph IV certification notices, court decisions affecting key patents, new ANDA approvals for the product, or regulatory exclusivity changes. These events require a response decision, sometimes within days, and the client who learns about them from a competitor or from counsel in pending litigation rather than from their monitoring service will not renew the retainer.<\/p>\n\n\n\n

Quality Control and Legal Review<\/h3>\n\n\n\n

The patent landscape update, if it contains legal opinions or assessments of patent validity, constitutes legal work product and carries the professional responsibility implications of any client legal advice. Your firm’s quality control process for landscape reports should include attorney review of all validity and enforceability assessments, a conflicts check for any products where your firm has worked for both brand and generic clients, and appropriate privilege designations for reports that are prepared in anticipation of litigation.<\/p>\n\n\n\n

The privilege question is particularly important. A landscape report prepared as part of a litigation readiness exercise may be protected as work product; the same analysis prepared as a business planning document may be discoverable. Clients should understand this distinction, and your engagement letters should reflect it. The most defensible approach is to treat pre-LOE landscape work as litigation-anticipation work product from the outset, given that Paragraph IV challenges are a foreseeable consequence of LOE for virtually any commercially significant product.<\/p>\n\n\n\n

International Patent Strategy in the Pre-LOE Window<\/h2>\n\n\n\n

U.S.-focused patent analysis captures the largest single market but misses the strategic picture for products with significant international revenue. The European Union’s Supplementary Protection Certificate (SPC) system, Japan’s patent term extension program, and Canada’s Certificate of Supplementary Protection each create additional exclusivity periods that can extend commercial protection significantly beyond the base patent term. These programs have different eligibility requirements and calculation methodologies, which means a product’s effective global exclusivity timeline requires country-by-country analysis rather than a uniform application of U.S. rules.<\/p>\n\n\n\n

The pre-LOE landscape for a product generating 50 percent of its revenue in Europe should include SPC status for Germany, France, the UK post-Brexit, Italy, and Spain at minimum. European SPCs can add up to five years of exclusivity to the base patent term, and their scope can differ from the underlying patent if the SPC was granted for a specific formulation or combination product. Generic manufacturers in Europe file SPC challenges with regularity, and the outcomes of those challenges can affect the competitive timeline in ways that feed directly into the client’s global LOE strategy.<\/p>\n\n\n\n

The practical limitation for most U.S. regulatory and legal firms is the depth of foreign patent expertise required to produce credible international landscape analysis. Two models work: building relationships with correspondent firms in key jurisdictions who can provide local patent analysis on a subcontract basis, or focusing the international section of the landscape on the publicly available data — SPC filings, patent expirations tracked in international databases, generic manufacturer approval activities — and recommending foreign counsel engagement for any jurisdiction where a material strategic decision is pending.<\/p>\n\n\n\n

Key Takeaways<\/h2>\n\n\n\n
    \n
  • The five-year pre-LOE window is when strategic action is still available. Patent landscape intelligence delivered inside 24 months of LOE is largely reactive; outside five years, it is strategic.<\/li>\n\n\n\n
  • Patent landscape updates are more than Orange Book searches. The service value comes from reconciling listed and unlisted patents, mapping secondary patent webs, covering international filings, and connecting patent analysis to regulatory exclusivity periods.<\/li>\n\n\n\n
  • Regulatory and legal firms have a structural advantage over pure analytics vendors because pre-LOE patent strategy is inseparable from regulatory strategy: PTEs, pediatric exclusivity, Orange Book listing eligibility, and SPC management all require FDA expertise alongside patent expertise.<\/li>\n\n\n\n
  • DrugPatentWatch is the most efficient foundation for pre-LOE intelligence workflows. It handles the data aggregation that would otherwise consume the analyst’s time and allows your team to focus on interpretation and strategic advice.<\/li>\n\n\n\n
  • Paragraph IV certification filings are the most actionable competitive intelligence signals in the pre-LOE window. Monitor them continuously and communicate them to clients immediately.<\/li>\n\n\n\n
  • Price the service on value, not hours. A landscape analysis that identifies a listable secondary patent can protect years of revenue worth 100 to 1,000 times the fee. The fee conversation should start with that asymmetry.<\/li>\n\n\n\n
  • The monitoring retainer model is more valuable than one-time reports for both firm economics and client outcomes. Build the retainer protocol into the initial landscape deliverable as a natural next step.<\/li>\n\n\n\n
  • Biologic patent estates are categorically more complex than small-molecule estates. BPCIA patent dance dynamics and manufacturing patent clusters require specialized attention that distinguishes sophisticated service providers from commodity vendors.<\/li>\n<\/ul>\n\n\n\n

    FAQ<\/h2>\n\n\n\n

    How does a regulatory and legal firm differentiate its patent landscape service from what a client’s in-house team or a pure data vendor can produce?<\/h4>\n\n\n\n

    The differentiation is in the integration of regulatory and patent expertise. A data vendor delivers comprehensive patent listings efficiently but cannot tell a client whether a specific secondary patent meets FDA’s criteria for Orange Book listing, or whether a label amendment could support a new exclusivity period. An in-house team can interpret both dimensions but is managing many products simultaneously and may not have the bandwidth for continuous monitoring. An external regulatory and legal firm that combines patent analysis with regulatory strategy delivers advice that neither an analytics vendor nor an overextended in-house team can match.<\/p>\n\n\n\n

    What is the biggest risk in pre-LOE patent landscape services, and how should a firm manage it?<\/h4>\n\n\n\n

    The biggest operational risk is missed material changes — a Paragraph IV certification notice or a new ANDA approval that the monitoring workflow fails to surface in time for the client to act. This risk is managed through alert infrastructure (DrugPatentWatch and USPTO monitoring alerts), clear escalation protocols within the firm, and engagement letters that define response time commitments for material events. The reputational risk of a client learning about a Paragraph IV challenge from a competitor before hearing it from their monitoring service is severe enough to warrant treating the monitoring function as a compliance obligation rather than a best-effort service.<\/p>\n\n\n\n

    How should a firm handle conflicts when it represents both brand manufacturers and generic companies?<\/h4>\n\n\n\n

    Most regulatory and legal firms with pre-LOE patent landscape practices have conflict policies that prohibit simultaneous representation of brand manufacturers and generic manufacturers for the same product. The practical management issue arises when a firm has a brand monitoring engagement and a generic manufacturer approaches it for landscape work on the same product. The screening process for new business development engagements should run conflict checks against the entire product-level monitoring portfolio, not just the client-level check that suffices for most legal work. Some firms resolve this by creating separate practice groups with distinct conflict pools for brand and generic clients.<\/p>\n\n\n\n

    At what point does a pre-LOE patent landscape service transition into full patent litigation support?<\/h4>\n\n\n\n

    The transition is not automatic, but it is natural. A firm that has maintained a monitoring engagement for a product and understands its patent estate comprehensively is the obvious choice for litigation support when a Paragraph IV challenge materializes. The landscape work has already produced the patent-by-patent analysis, the competitive intelligence on the generic filer, and the strategic framing that litigation counsel needs. The business development opportunity in pre-LOE services is precisely this: the monitoring engagement is the relationship that positions the firm for the much larger litigation engagement when the challenge arrives. Structuring the monitoring scope to include litigation readiness assessment from the outset makes the transition explicit rather than assumed.<\/p>\n\n\n\n

    How do LOE dynamics differ for biologics compared to small molecules, and does that change the service model?<\/h4>\n\n\n\n

    The fundamental difference is in the patent estate complexity and the regulatory exclusivity structure. Biologic patent estates can include hundreds of patents across manufacturing, formulation, and clinical dimensions, compared to the smaller portfolios typical of small molecules. The BPCIA’s 12-year data exclusivity period means that the relevant strategic window starts earlier for biologics — the 12-year countdown begins at first licensure, and biosimilar applicants begin development work years before that clock expires. The service model for biologic pre-LOE intelligence should weight manufacturing and process patent analysis more heavily, track 351(l) patent dance developments as a primary competitive signal, and incorporate the payer contracting and formulary competition dynamics that differ significantly from small-molecule generic entry. The subscription retainer model is particularly appropriate for biologics because of the extended monitoring horizon and the higher frequency of material developments in complex patent estates.<\/p>\n\n\n\n

    References<\/h2>\n\n\n\n
      \n
    1. IQVIA Institute for Human Data Science. (2024). The global use of medicines 2024: Outlook to 2028.<\/em> IQVIA Institute. https:\/\/www.iqvia.com\/insights\/the-iqvia-institute\/reports\/the-global-use-of-medicines-2024<\/li>\n\n\n\n
    2. Berndt, E. R., Mortimer, R., Bhattacharjya, A., Parece, A., & Tuttle, E. (2007). Authorized generic drugs, price competition, and consumers’ welfare. Health Affairs, 26<\/em>(3), 790-799. https:\/\/doi.org\/10.1377\/hlthaff.26.3.790<\/li>\n\n\n\n
    3. Sagonowsky, E. (2023, January). AbbVie’s Humida faces biosimilar avalanche: Here’s the rundown. Fierce Pharma.<\/em> https:\/\/www.fiercepharma.com\/pharma\/abbvie-humira-biosimilar-competition-summary<\/li>\n\n\n\n
    4. Licensing Executives Society (USA & Canada). (2024). Pharmaceutical IP management survey: In-house perspectives on portfolio monitoring.<\/em> LES. https:\/\/www.les.org<\/li>\n\n\n\n
    5. Caraco Pharmaceutical Laboratories, Ltd. v. Novo Nordisk A\/S, 566 U.S. 399 (2012).<\/li>\n\n\n\n
    6. Initiative for Medicines, Access & Knowledge (I-MAK). (2023). Overpatented, overpriced: How excessive pharmaceutical patenting is extending monopolies and driving up drug prices.<\/em> I-MAK. https:\/\/www.i-mak.org\/overpatented-overpriced<\/li>\n<\/ol>\n","protected":false},"excerpt":{"rendered":"

      The Five-Year Window Is Not Generous When a branded drug loses patent exclusivity, its manufacturer does not get to negotiate […]<\/p>\n","protected":false},"author":1,"featured_media":37188,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_lmt_disableupdate":"","_lmt_disable":"","site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"categories":[10],"tags":[],"class_list":["post-37185","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-insights"],"modified_by":"DrugPatentWatch","_links":{"self":[{"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/posts\/37185","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/comments?post=37185"}],"version-history":[{"count":2,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/posts\/37185\/revisions"}],"predecessor-version":[{"id":37190,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/posts\/37185\/revisions\/37190"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/media\/37188"}],"wp:attachment":[{"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/media?parent=37185"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/categories?post=37185"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/tags?post=37185"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}